LASMIDITAN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H18F3N3O2
Molecular Weight	377.3603
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of LASMIDITAN

Structure Search

SMILES

CN1CCC(CC1)C(=O)C2=CC=CC(NC(=O)C3=C(F)C=C(F)C=C3F)=N2

InChI

InChIKey=XEDHVZKDSYZQBF-UHFFFAOYSA-N

InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)

HIDE SMILES / InChI

Molecular Formula	C19H18F3N3O2
Molecular Weight	377.3603
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:42:18 UTC 2023` Edited by `admin` on `Fri Dec 15 16:42:18 UTC 2023`
Record UNII	760I9WM792
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LASMIDITAN

Official Name

English

Lasmiditan [WHO-DD]

Common Name

English

2,4,6-Trifluoro-N-{6-[(1-methylpiperidine-4-yl)carbonyl]pyridin-2-yl}benzamide

Systematic Name

English

COL-144

Code

English

lasmiditan [INN]

Common Name

English

LASMIDITAN [MI]

Common Name

English

LASMIDITAN [USAN]

Common Name

English

Classification Tree Code System Code

DEA NO.

2790

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

Code System Code Type Description

FDA UNII

760I9WM792

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

INN

9176

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

WIKIPEDIA

LASMIDITAN

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

DAILYMED

760I9WM792

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

PUBCHEM

11610526

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

SMS_ID

100000172980

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

ChEMBL

CHEMBL3039520

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

EPA CompTox

DTXSID40469435

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

MERCK INDEX

m12168

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

DRUG BANK

DB11732

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

DRUG CENTRAL

5351

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

USAN

ZZ-66

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

NCI_THESAURUS

C166996

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

LACTMED

Lasmiditan

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

RXCUI

2256930

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

CAS

439239-90-4

Created by admin on Fri Dec 15 16:42:18 UTC 2023 , Edited by admin on Fri Dec 15 16:42:18 UTC 2023

PRIMARY

Related Record Type Details


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE

Comments:

In vitro studies showed that lasmiditan is a substrate of P-gp. However, lasmiditan is a BCS Class I drug and is unlikely to be affected by P-gp inhibitors.


					760I9WM792

EXCRETED UNCHANGED

Interaction Type:

AMOUNT EXCRETED

Qualification:

URINE

Amount:


					76UB6O122H

ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2

TRANSPORTER -> INHIBITOR

Comments:

Lasmiditan is an in-vitro inhibitor of P-gp and BCRP.


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> INHIBITOR

Comments:

Lasmiditan is an in-vitro inhibitor of P-gp and BCRP.


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Comments:

The human plasma protein binding of lasmiditan is approximately 55% to 60% and independent of concentration between 15 and 500 ng/mL.

Interaction Type:

BINDING

Amount:


					W64YBJ346B

LASMIDITAN SUCCINATE

SALT/SOLVATE -> PARENT


					H7A23C6P5F

LASMIDITAN HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					760I9WM792

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC

Tmax	PHARMACOKINETIC				ORAL ADMINISTRATION